BEZ235 (NVP-BEZ235, Dactolisib)

Catalog No.S1009

BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure
Molecular Weight: 469.55

Validation & Quality Control

Product Use Citation(81)

Customer Product Validation(8)

Quality Control & MSDS

Related Compound Libraries

BEZ235 (NVP-BEZ235, Dactolisib) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.
Targets p110α [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
mTOR (p70S6K) [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)

 View  More

IC50 4 nM 5 nM 6 nM 7 nM
In vitro BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. [1] BEZ235 is an mTORC1/2 catalytic inhibitor. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Trypanosoma brucei bruceiMlWzRY51cW2rY4LvZolidCCDc4PhfS=>MX2xPEBpMn;ESG1UVw>?MnG3RY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?Mo\hNlQ5ODV7NE[=
MCF7MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPnSGkxNjBzLUGwNEDPxE1?NYq5TJNHPDhiaB?=MUfEUXNQMYjJR|UxRTBwN{Og{txOMmnaNlM5PzF7MES=
HCT116MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHiNE4xOS1zMECg{txOMkf3OFghcA>?MlnxSG1UVw>?MX3JR|UxRTFwMU[g{txOMWiyN|g4OTlyNB?=
U87MGMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYiwMlAyNTFyMDFOwG0>MYW0PEBpMXTEUXNQM{LVfmlEPTB;MT6zNkDPxE1?MVmyN|g4OTlyNB?=
HBC4NH7QOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3OzNlAvODFvMUCwJO69VQ>?NGfN[401QCCqM17iNGxw\yCJSUWwQU05NjZzIF2=M4jkVlIzOzN4MkS2
BSY1NUDrXppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnyV242OC5yMT2xNFAh|ryPM3rPb|Q5KGh?MUDMc4chT0l3ME2tPE41QCCPMWeyNlM{PjJ2Nh?=
HBC5NWTnZVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXz3TVRSOC5yMT2xNFAh|ryPM1vPTlQ5KGh?MmfTUI9oKEeLNUC9MVcvQDdiTR?=NFXqUI0zOjN|NkK0Oi=>
MCF7NXLO[IlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGH3VoExNjBzLUGwNEDPxE1?MojYOFghcA>?NV3DNJNGVG:pIFfJOVA:NThwMU[gUS=>M4rJb|IzOzN4MkS2
MDA-MB-231NV[yVZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHW1emYxNjBzLUGwNEDPxE1?MXK0PEBpNWfnSlV[VG:pIFfJOVA:NThwMEmgUS=>NY\aZXluOjJ|M{[yOFY>
U251Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTDR3pxOC5yMT2xNFAh|ryPNWL6SnFZPDhiaB?=NVGxXXVjVG:pIFfJOVA:NTdwNk[gUS=>NHHqXHAzOjN|NkK0Oi=>
SF268M3rKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{T4c|AvODFvMUCwJO69VQ>?NXTyNWRvPDhiaB?=M1jnW2xw\yCJSUWwQU04Njl{IF2=Mkn2NlI{OzZ{NE[=
SF295MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofnNE4xOS1zMECg{txOMX:0PEBpNVX2TYRKVG:pIFfJOVA:NThwM{GgUS=>M3LhZVIzOzN4MkS2
SF539NX7aNFhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLSRmoxNjBzLUGwNEDPxE1?NHPYN2g1QCCqNHjFN2xNd2diR1m1NF0uQC53OTDNM2DkWlIzOzN4MkS2
SNB75NWDa[5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;tVJdlOC5yMT2xNFAh|ryPMnP4OFghcA>?MnvkUI9oKEeLNUC9MVgvPThiTR?=M1\UeVIzOzN4MkS2
SNB78NEDEXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYSwMlAyNTFyMDFOwG0>MmXsOFghcA>?MmfEUI9oKEeLNUC9MVgvPjViTR?=NYHKSYFSOjJ|M{[yOFY>
HCC2998M2jQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPUZYxbOC5yMT2xNFAh|ryPNEnRcoI1QCCqM{HQPWxw\yCJSUWwQU05NjB3IF2=M2rJU|IzOzN4MkS2
KM12M2XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUf5fG5FOC5yMT2xNFAh|ryPMYG0PEBpNX3lO5FKVG:pIFfJOVA:NTdwNUSgUS=>MljzNlI{OzZ{NE[=
HT-29MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU[wMlAyNTFyMDFOwG0>Mkf1OFghcA>?NVew[I15VG:pIFfJOVA:NTdwN{WgUS=>NIjKXo8zOjN|NkK0Oi=>
HCT15MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFn2WpgxNjBzLUGwNEDPxE1?MoLEOFghcA>?MnjQUI9oKEeLNUC9MVgvODNiTR?=M3HTS|IzOzN4MkS2
HCT116NV[4V246T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPzUGVpOC5yMT2xNFAh|ryPNWLHdGJ{PDhiaB?=M2\jNGxw\yCJSUWwQU04NjZzIF2=NUixVZNDOjJ|M{[yOFY>
NCI-H23NFjTbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHH[3gxNjBzLUGwNEDPxE1?M3PUPVQ5KGh?NGLqd49Nd2diR1m1NF0uPy54NDDNMo\yNlI{OzZ{NE[=
NCI-H226M3nnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnJNHZiOC5yMT2xNFAh|ryPNFLtNVk1QCCqNFXlbo5Nd2diR1m1NF0uQC52NDDNMVqyNlM{PjJ2Nh?=
NCI-H522Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vsclAvODFvMUCwJO69VQ>?Moj4OFghcA>?MVjMc4chT0l3ME2tPE41PSCPMnrvNlI{OzZ{NE[=
NCI-H438M4TXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITr[XMxNjBzLUGwNEDPxE1?MkHVOFghcA>?NYHWS|BmVG:pIFfJOVA:NThwMUGgUS=>MlntNlI{OzZ{NE[=
A549MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYewMlAyNTFyMDFOwG0>Mni0OFghcA>?NUHpe|FWVG:pIFfJOVA:NThwMEegUS=>NWn6fGI3OjJ|M{[yOFY>
DMS273NUToVnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HQOVAvODFvMUCwJO69VQ>?MV20PEBpMXTMc4chT0l3ME2tO{45OCCPNXvIbHBNOjJ|M{[yOFY>
DMS114NWDyOJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHVWI5mOC5yMT2xNFAh|ryPMoDZOFghcA>?NHexXY5Nd2diR1m1NF0uQC5|OTDNM3jGfFIzOzN4MkS2
LOXIMVINVzhfWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnKdpMxNjBzLUGwNEDPxE1?Ml71OFghcA>?M2HFPWxw\yCJSUWwQU05NjZ4IF2=NH3NcWgzOjN|NkK0Oi=>
OVCAR3NXjkUJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq1V5JoOC5yMT2xNFAh|ryPMknsOFghcA>?M4PwSGxw\yCJSUWwQU05NjF5IF2=MkX0NlI{OzZ{NE[=
OVCAR4Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\3dlAvODFvMUCwJO69VQ>?NFfoXHk1QCCqMWTMc4chT0l3ME2tPE42QCCPMWWyNlM{PjJ2Nh?=
OVCAR5NEHvSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jsRVAvODFvMUCwJO69VQ>?M33wVVQ5KGh?MkXBUI9oKEeLNUC9MVcvPTdiTR?=NWj2RmhQOjJ|M{[yOFY>
OVCAR8M4G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\n[3IxNjBzLUGwNEDPxE1?NEK4co01QCCqNILNOWhNd2diR1m1NF0uPy56NDDNNWjmUGl5OjJ|M{[yOFY>
SKOV3NF7ydJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnsVmszOC5yMT2xNFAh|ryPNUHO[llHPDhiaB?=MWTMc4chT0l3ME2tPE41OSCPNFPrdXAzOjN|NkK0Oi=>
RXF631LNYSyOoM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PvPFAvODFvMUCwJO69VQ>?NFjuSWU1QCCqNFHkV3ZNd2diR1m1NF0uQC5{MTDNM2POXVIzOzN4MkS2
ACHNM2\2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWiwMlAyNTFyMDFOwG0>NWPYTZR5PDhiaB?=MkizUI9oKEeLNUC9MVcvQTViTR?=NWPiVIlQOjJ|M{[yOFY>
St-4NFvseJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXPO4xuOC5yMT2xNFAh|ryPMXO0PEBpNYK4eGVpVG:pIFfJOVA:NTdwNEegUS=>NFjVNoYzOjN|NkK0Oi=>
MKN1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Kz[|AvODFvMUCwJO69VQ>?Ml;sOFghcA>?NETYWWJNd2diR1m1NF0uQC52MTDNMYGyNlM{PjJ2Nh?=
MKN7MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{iyNlAvODFvMUCwJO69VQ>?NUTBdJdMPDhiaB?=NWfYUHRJVG:pIFfJOVA:NTdwNkigUS=>Mo\zNlI{OzZ{NE[=
MKN28NUC2SHVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXpOIwxNjBzLUGwNEDPxE1?NV\FUVAzPDhiaB?=MonJUI9oKEeLNUC9MVcvODdiTR?=MmHpNlI{OzZ{NE[=
MKN45M4rOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTOTodTOC5yMT2xNFAh|ryPNYDyd4NqPDhiaB?=Ml7MUI9oKEeLNUC9MVgvOzRiTR?=NVnPeG9OOjJ|M{[yOFY>
MKN74NVzTNWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjL[pUxNjBzLUGwNEDPxE1?MUO0PEBpM{nh[Wxw\yCJSUWwQU04NjR{IF2=NXj6NpRnOjJ|M{[yOFY>
DU145MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDLbI4xNjBzLUGwNEDPxE1?MXW0PEBpNIHsZnhNd2diR1m1NF0uQC5zNjDNM{S5TFIzOzN4MkS2
PC3NVLVVZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnMbJhiOC5yMT2xNFAh|ryPMnTsOFghcA>?M2rwNWxw\yCJSUWwQU05NjZ4IF2=NGXCZm8zOjN|NkK0Oi=>
Trypanosoma brucei bruceiMnnRSpVv[3Srb36gRZN{[Xl?M1zUdFIxOCCwTR?=MV6xNkBpMVzEUXNQM2Ple2Rm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?NHLRNZYzPDhyNUm0Oi=>
Trypanosoma brucei bruceiM2DnZ2Z2dmO2aX;uJGF{e2G7NHXSN|QyQCCqM1z0WGROW09?M2nTW2lvcGmkaYTpc44hd2ZicnXj[ZB1d3JvbXXkbYF1\WRiZX7kc4N6fG:|aYOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5idILhcpNn\XK{aX6geZB1[WunM3v3NVI1QDB3OUS2
Trypanosoma brucei bruceiMUPGeY5kfGmxbjDBd5NigQ>?NWC3OZlZOjByIH7NNH3HUpYyOiCqMWLEUXNQMlnMSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>MXuyOFgxPTl2Nh?=
Trypanosoma brucei bruceiNYPxfFFITnWwY4Tpc44hSXO|YYm=MoPhNlAxKG6PNV\jeYdCOTJiaB?=NGLPfo5FVVORNIrOfW1G\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>MoXSNlQ5ODV7NE[=
UM-UC-3M{HYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPGTWM2OD1|MUWgdG0>MVfTRW5ITVJ?
SBC-1NGXkd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTOTWM2OD15NEKgdG0>M1H3ZXNCVkeHUh?=
MKN1NH3xUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\lXW9oUUN3ME2yMlghdk1?M2m4WnNCVkeHUh?=
NCI-H720MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvGTWM2OD1|LkW3JI5OM33PfHNCVkeHUh?=
BFTC-909NXzWWVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1H1bmlEPTB;Mz63NUBvVQ>?MmfTV2FPT0WU
BPH-1M3rrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTRwN{[gcm0>M2TFeHNCVkeHUh?=
PC-3NUfU[VBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTVwMEmgcm0>NHXwPJNUSU6JRWK=
AN3-CANFLTfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLYW|lDUUN3ME21MlU3KG6PNYqzPXZvW0GQR1XS
HNMnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLKTWM2OD13Lkm2JI5OM33QTXNCVkeHUh?=
HCC2218NFm4TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LXT2lEPTB;Nj62NUBvVQ>?NWjzTJpKW0GQR1XS
KP-4MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTdibl2=MVjTRW5ITVJ?
LU-139NVG1O|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT6[3BQUUN3ME23Mlc4KG6PNWHWZlhRW0GQR1XS
ETK-1MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\GZmhkUUN3ME23Mlg5KG6PNHjpd2RUSU6JRWK=
Ramos-2G6-4C10MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTzPHY4UUN3ME24MlQ6KG6PM{jJOHNCVkeHUh?=
MHH-PREB-1NIXwfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1X5emlEPTB;OT6xNkBvVQ>?NIPZWVdUSU6JRWK=
DU-4475M1eyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPwTWM2OD17LkS0JI5OMYXTRW5ITVJ?
NCI-H1666NX;CbHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljxTWM2OD17LkexJI5OM3fKfnNCVkeHUh?=
CAMA-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTlwODDuUS=>M{e3b3NCVkeHUh?=
TYK-nuMmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLHTWM2OD17Lkm0JI5OMmT5V2FPT0WU
MFE-280NWnsTpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorvTWM2OD17Lkm5JI5OM1HpPHNCVkeHUh?=
A549NXrOcJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M365PWlEPTB;MUCuNVQhdk1?NH;zemhUSU6JRWK=
769-PMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFyLkS0JI5OMo[xV2FPT0WU
L-363Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn63TWM2OD1zMD62PUBvVQ>?MnPJV2FPT0WU
ES8NIDxdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nJXGlEPTB;MUCuPUBvVQ>?MVrTRW5ITVJ?
PA-1M{CzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT0V3pKSzVyPUGxMlgzKG6PMkXjV2FPT0WU
MewoMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojETWM2OD1zMT65PUBvVQ>?M1HSbnNCVkeHUh?=
HSC-3NUDO[oNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDxZpp3UUN3ME2xNk4zOSCwTR?=MoOzV2FPT0WU
H4MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH4TWM2OD1zMj62O{BvVQ>?NITUcHdUSU6JRWK=
BB65-RCCNXPEVYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlyyTWM2OD1zMj63NkBvVQ>?MnzxV2FPT0WU
NCI-H1793MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF{LkiyJI5ONUnYVGJEW0GQR1XS
KARPAS-45NUL4RmdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWD1b3JZUUN3ME2xN{42OSCwTR?=NGj1cW1USU6JRWK=
GCTMoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfHe2JKUUN3ME2xN{43QCCwTR?=M2\MbXNCVkeHUh?=
EoL-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXkZYRKSzVyPUGzMlk{KG6PMmHEV2FPT0WU
LB2241-RCCNHqzSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLuTWM2OD1zND6wNUBvVQ>?NEjJemlUSU6JRWK=
ES5NIPwNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLhd5dKUUN3ME2xOE44PCCwTR?=MnTnV2FPT0WU
LOXIMVINFzrUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHK4RpVKSzVyPUG0Mlk6KG6PNVrNbVB7W0GQR1XS
COR-L105MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoewTWM2OD1zNT6wOEBvVQ>?Mlf1V2FPT0WU
P12-ICHIKAWAMm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPOTWM2OD1zNT6xJI5OMUHTRW5ITVJ?
CHL-1M13RV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LN[2lEPTB;MUWuOFUhdk1?MWnTRW5ITVJ?
VMRC-RCZMmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnZZmVKSzVyPUG1MlY{KG6PMWPTRW5ITVJ?
HHMn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELINJZKSzVyPUG1Mlchdk1?MUjTRW5ITVJ?
NUGC-3MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{X5VWlEPTB;MU[uN|Qhdk1?MojtV2FPT0WU
EGI-1M{T0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF4LkSzJI5ONITFcXBUSU6JRWK=
OS-RC-2NIjLe|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTF4LkS3JI5OMV;TRW5ITVJ?
MOLT-16Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF5LkG1JI5OMnTrV2FPT0WU
NCI-H209MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLYc3RKSzVyPUG3MlI6KG6PMVPTRW5ITVJ?
697NH7iTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTQNHdmUUN3ME2xO{41OyCwTR?=MmrQV2FPT0WU
D-56MGMoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEezVGVKSzVyPUG3MlY6KG6PMlz5V2FPT0WU
VA-ES-BJMmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTF5LkizJI5OMUHTRW5ITVJ?
EW-16NFXVdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nXUmlEPTB;MUiuNFQhdk1?MWfTRW5ITVJ?
HGC-27MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrscW9KUUN3ME2xPE4xPiCwTR?=MV;TRW5ITVJ?
ES7NEfhWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvpTWM2OD1zOD6wPUBvVQ>?NGPrXIVUSU6JRWK=
HuH-7MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPpTWM2OD1zOD60JI5OM3;BXHNCVkeHUh?=
BCPAPNVP4ZlNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEn6TphKSzVyPUG4MlY2KG6PM3\yT3NCVkeHUh?=
SW1710Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPNTWM2OD1zOD63NkBvVQ>?NH;mVJRUSU6JRWK=
IST-MEL1MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHDOI1KSzVyPUG4Mlc4KG6PNI\FWYxUSU6JRWK=
SF295M3PsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHxTWM2OD1zOD65N{BvVQ>?NHqyWmVUSU6JRWK=
RPMI-7951Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfYcItKSzVyPUG5MlI5KG6PMkn2V2FPT0WU
SF126MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrCZ2N5UUN3ME2xPU41OSCwTR?=MlLRV2FPT0WU
GAMGMoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF7LkS4JI5OMlPMV2FPT0WU
KNS-81-FDMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3PUIRKSzVyPUG5MlU1KG6PMkLFV2FPT0WU
RT-112MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnm4TWM2OD1zOT62OkBvVQ>?M1XkRXNCVkeHUh?=
DELNGXvO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGe4eXZKSzVyPUKwMlQ6KG6PM4mzW3NCVkeHUh?=
CGTH-W-1NYjBUVVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPzboVDUUN3ME2yNE43OyCwTR?=M1TtfXNCVkeHUh?=
HOSMmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1r0R2lEPTB;MkGuNFYhdk1?NHL3UHVUSU6JRWK=
ES4M2Pve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrOZ4FKSzVyPUKxMlA5KG6PNVfS[VZNW0GQR1XS
RXF393NHfUc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVviW5c4UUN3ME2yNU41PSCwTR?=MXfTRW5ITVJ?
NCI-H2030MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33mZWlEPTB;MkGuOVIhdk1?NIXVSopUSU6JRWK=
YH-13M3rzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7jTWM2OD1{MT64PEBvVQ>?MUjTRW5ITVJ?
HT-1080MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PhOmlEPTB;MkGuPVMhdk1?MV\TRW5ITVJ?
NCI-SNU-1MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LHSWlEPTB;MkGuPVUhdk1?M4HnXHNCVkeHUh?=
G-402M1PWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH0TWlbUUN3ME2yNk4yPiCwTR?=M{K1W3NCVkeHUh?=
786-0Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTJ{LkK5JI5ONHn4bmhUSU6JRWK=
ME-180M3u4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfMcpdKSzVyPUKyMlQ{KG6PMUnTRW5ITVJ?
NB69MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTJ{LkWzJI5ONWjTWFR4W0GQR1XS
J-RT3-T3-5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\5SmlEPTB;MkKuPVYhdk1?NVzoTGg2W0GQR1XS
TGBC1TKBMlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y5T2lEPTB;MkOuNFUhdk1?M3Hyc3NCVkeHUh?=
SW780MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJ|LkGzJI5ONF\v[2lUSU6JRWK=
MG-63NIfQbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTnclhHUUN3ME2yN{41PSCwTR?=NES3UVVUSU6JRWK=
BV-173NIfFUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFi5PHBKSzVyPUKzMlg4KG6PM1rYfHNCVkeHUh?=
CAL-51M3zC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\zTWM2OD1{Mz64PUBvVQ>?M{DJRnNCVkeHUh?=
A375NV;6clVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTPTWM2OD1{Mz65N{BvVQ>?NG\nNWlUSU6JRWK=
MEL-HONXfVNlc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXztS|ByUUN3ME2yOE4xPCCwTR?=MVfTRW5ITVJ?
EFO-27MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJ2LkOzJI5OMoP2V2FPT0WU
Hs-578-TMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PQVWlEPTB;MkSuOVghdk1?NHXFXmpUSU6JRWK=
NBsusSRMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7nTWM2OD1{ND62JI5ONEPWUJdUSU6JRWK=
CTB-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3i0fGlEPTB;MkSuOlchdk1?MWLTRW5ITVJ?
FTC-133MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;Z[YdmUUN3ME2yOU4yKG6PMVnTRW5ITVJ?
MOLT-4NXXZSlN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV34XItPUUN3ME2yOU4yOiCwTR?=M2G5UHNCVkeHUh?=
HO-1-N-1NW\PcmJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\mTWM2OD1{NT6xOUBvVQ>?MV3TRW5ITVJ?
ES3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{L1d2lEPTB;MkWuNlIhdk1?MVLTRW5ITVJ?
TI-73MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUm4[HM4UUN3ME2yOU4zQCCwTR?=MWXTRW5ITVJ?
MPP-89NIO4c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTnO3ZKSzVyPUK1MlMzKG6PNV\HPJl1W0GQR1XS
KYSE-150MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\MW4xSUUN3ME2yOU45QSCwTR?=MUDTRW5ITVJ?
LXF-289MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rkfWlEPTB;Mk[uNFQhdk1?NWDQNVZVW0GQR1XS
SK-LU-1MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4q0[GlEPTB;Mk[uNVchdk1?M3Ls[XNCVkeHUh?=
HOP-92M1naZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlKyTWM2OD1{Nj60PEBvVQ>?MmPJV2FPT0WU
HuO9M{PUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJ4Lke2JI5OMlv1V2FPT0WU
SW962NIfMd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjONppoUUN3ME2yOk44PiCwTR?=NGfrdnNUSU6JRWK=
RS4-11MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTJ4LkmxJI5OM1T3ZnNCVkeHUh?=
NCI-H292M{nJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DQRmlEPTB;Mkegcm0>M{PPTHNCVkeHUh?=
DBNYf3PJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUWzdYoyUUN3ME2yO{4{PiCwTR?=MoHIV2FPT0WU
SW1088MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\Cc2lEPTB;MkiuNlkhdk1?NHHhfWpUSU6JRWK=
A204MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7kdGF2UUN3ME2yPE41PyCwTR?=M2DxVHNCVkeHUh?=
A3-KAWNVq3b5VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJ6Lk[0JI5ONUKwOFZwW0GQR1XS
MV-4-11NG\OVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTJ6Lkegcm0>MmjiV2FPT0WU
ES1NYLKR4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJ6Lki0JI5ONV\ofFVmW0GQR1XS
ONS-76Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJ7LkC1JI5OMWrTRW5ITVJ?
D-263MGNYLKbFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7Ud5c4UUN3ME2yPU4{PSCwTR?=M3rNPHNCVkeHUh?=
U-2-OSMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfRTWM2OD1{OT61JI5OMYPTRW5ITVJ?
T98GMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXeyW3pwUUN3ME2yPU45QCCwTR?=NVvyZ4hFW0GQR1XS
GI-ME-NM1vKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXnTWM2OD1{OT65NUBvVQ>?M1u0fnNCVkeHUh?=
BHT-101NXS0WXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfmdGNIUUN3ME2zNE4xPSCwTR?=NITi[2lUSU6JRWK=
NOS-1M2PzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTNyLkGyJI5ONXrPUm5sW0GQR1XS
AsPC-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrKdmltUUN3ME2zNE4zKG6PNILU[Y5USU6JRWK=
QIMR-WILMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2D6SmlEPTB;M{CuOkBvVQ>?MWLTRW5ITVJ?
JVM-3M{OxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTNyLkizJI5OMXrTRW5ITVJ?
KU-19-19M1KwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLXTWM2OD1|MT6xN{BvVQ>?MlXrV2FPT0WU
OVCAR-8MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTNzLkK2JI5OMWrTRW5ITVJ?
BENMoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk[wTWM2OD1|MT62N{BvVQ>?MXfTRW5ITVJ?
BE-13NUT6e45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXDWnhKSzVyPUOxMlgzKG6PM1vWNXNCVkeHUh?=
EW-18M362dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jBW2lEPTB;M{GuPFYhdk1?MWDTRW5ITVJ?
ECC10MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\Je2lEPTB;M{GuPVUhdk1?MmXjV2FPT0WU
CTV-1NGPNUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVn6clFFUUN3ME2zNk45OiCwTR?=NE\qXoNUSU6JRWK=
COLO-800NVjsdZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnsO5VNUUN3ME2zNk46OiCwTR?=MlzDV2FPT0WU
A2058NYHlTHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTN|LkK1JI5ONE\sdopUSU6JRWK=
VM-CUB-1NUnxd4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTPTWM2OD1|Mz60N{BvVQ>?NEnnN3NUSU6JRWK=
Ca9-22NVLaUHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonKTWM2OD1|Mz61OUBvVQ>?MmPTV2FPT0WU
COLO-684M{PKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFuyR3pKSzVyPUOzMlU5KG6PMnjzV2FPT0WU
RPMI-8226NFH1[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkX1TWM2OD1|Mz64NkBvVQ>?NW\VeZoyW0GQR1XS
SK-NEP-1M4nUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfDeo1iUUN3ME2zOE4yPSCwTR?=MnG4V2FPT0WU
BeckerMmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LTOmlEPTB;M{SuNlEhdk1?MnjEV2FPT0WU
NCI-H28MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnXUGpKSzVyPUO0MlQ1KG6PM1jzNHNCVkeHUh?=
CAL-120MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVi1W3k1UUN3ME2zOE44OiCwTR?=NFLYW2ZUSU6JRWK=
MDA-MB-157NGmwOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvh[Hk3UUN3ME2zOU41OSCwTR?=MY\TRW5ITVJ?
OVCAR-5MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LWPWlEPTB;M{WuOFchdk1?MX\TRW5ITVJ?
LAMA-84NHXTTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHSzO45KSzVyPUO1Mlg4KG6PMV;TRW5ITVJ?
CAKI-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfa[nRDUUN3ME2zOk41OyCwTR?=NIThW5NUSU6JRWK=
DaoyNIO1R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mki1TWM2OD1|Nj63JI5ONWXKOmJkW0GQR1XS
CAL-62NVzkNYNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTN4Lki2JI5ONWHwemxpW0GQR1XS
8-MG-BAMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnIW4NIUUN3ME2zO{4zPSCwTR?=M1;OR3NCVkeHUh?=
8505CNIPzXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHaWVR1UUN3ME2zO{42OSCwTR?=MXvTRW5ITVJ?
LNCaP-Clone-FGCNYLK[GVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M133fWlEPTB;M{euOVkhdk1?M37LWHNCVkeHUh?=
CAL-39NW\rXHo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37JSGlEPTB;M{euPUBvVQ>?MVvTRW5ITVJ?
MN-60MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnVNlVKSzVyPUO3Mlk3KG6PNFL4[nRUSU6JRWK=
RKONH;ocIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jEdmlEPTB;M{iuN|Mhdk1?NXH6U5ZjW0GQR1XS
U251NFraXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\qSVd3UUN3ME2zPE41OyCwTR?=MnTVV2FPT0WU
SJSA-1NEjINVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYC4N3JLUUN3ME2zPE42PCCwTR?=NIXzRXZUSU6JRWK=
CAL-12TMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoraTWM2OD1|OD62JI5OMUPTRW5ITVJ?
HCC1419NX7SeoNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T5R2lEPTB;M{iuO|Ehdk1?NUP5R29NW0GQR1XS
CO-314NUTUXGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q1UmlEPTB;M{iuO|Qhdk1?NGLXRXRUSU6JRWK=
LB1047-RCCMnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DEUmlEPTB;M{iuPFEhdk1?NFv3OHlUSU6JRWK=
A101DNGD2c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFS2R2NKSzVyPUO4Mlk4KG6PMlrPV2FPT0WU
MDA-MB-175-VIIMmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTN7LkWxJI5OMWTTRW5ITVJ?
MZ2-MELM1jBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvIS4NKSzVyPUO5MlY3KG6PM1TaR3NCVkeHUh?=
NB5NEXyfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTRyLk[0JI5OMl\QV2FPT0WU
G-401NGnWWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LUPGlEPTB;NECuPFIhdk1?M4LweXNCVkeHUh?=
HTMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXxTWM2OD12MT6wNkBvVQ>?M4PS[XNCVkeHUh?=
8305CNG\Xc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXPTWM2OD12MT64O{BvVQ>?NHnMd2dUSU6JRWK=
BHYM3XUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXJRnFKSzVyPUSyMlczKG6PNX\1O2xFW0GQR1XS
NTERA-S-cl-D1M{L5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXVRnFKSzVyPUSzJI5ONE[3TpJUSU6JRWK=
T-24NHnxOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTR|LkizJI5OMUHTRW5ITVJ?
EPLC-272HM{C2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTR2LkO5JI5OMXTTRW5ITVJ?
PSN1M2Xse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\KXWlEPTB;NESuOEBvVQ>?MlnSV2FPT0WU
NCI-H2452NYXsOYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTXXXdTUUN3ME20OE42QCCwTR?=NVnhdpFPW0GQR1XS
KS-1NGXKU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTR2Lk[2JI5OMVvTRW5ITVJ?
HD-MY-ZMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmn4TWM2OD12ND65NkBvVQ>?NIj5NHpUSU6JRWK=
KNS-62MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXwTY1KSzVyPUS1MlM5KG6PMVnTRW5ITVJ?
NOMO-1M1S1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[xR2RKSzVyPUS1Mlg4KG6PNX\RflVXW0GQR1XS
SK-HEP-1Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHufpZxUUN3ME20Ok4xPCCwTR?=NImyeWpUSU6JRWK=
IGR-1M2\xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTR4LkGzJI5OM3vZU3NCVkeHUh?=
KYSE-180NHTKXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn2zTWM2OD12Nj6xO{BvVQ>?NFrMZmJUSU6JRWK=
EW-22M{TYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHz0VGpKSzVyPUS2MlIhdk1?M{LCUXNCVkeHUh?=
NCI-H1355MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTR4LkO0JI5ONETQU3FUSU6JRWK=
DOHH-2MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjifItzUUN3ME20Ok4{PyCwTR?=MUnTRW5ITVJ?
A4-FukNVvNZ4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmyT4tJUUN3ME20Ok42OiCwTR?=MkL3V2FPT0WU
PC-14NYL2VVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrZUpdjUUN3ME20Ok42PyCwTR?=NV71fol6W0GQR1XS
TE-5M1jHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTR4Lki0JI5OMnTaV2FPT0WU
LB996-RCCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq5[2RtUUN3ME20O{4yQSCwTR?=MXTTRW5ITVJ?
NCI-H1623M4\wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnoTWM2OD12Nz63OkBvVQ>?NUHOTWl5W0GQR1XS
NCI-H1155MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTR6LkOyJI5OMWjTRW5ITVJ?
LoVoNIrwc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTDTWM2OD12OD60JI5OMlr4V2FPT0WU
MCF7NUHB[40zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXe1PJZLUUN3ME20PE42QCCwTR?=MkPzV2FPT0WU
AGSM{TZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrOUZNKSzVyPUS4Mlc4KG6PNGfHTZVUSU6JRWK=
PFSK-1M1myN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTR7LkC2JI5ONIP2XFFUSU6JRWK=
22RV1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPBTWM2OD12OT6wPUBvVQ>?NHG0d2hUSU6JRWK=
COR-L23NGSz[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfhblFKSzVyPUS5MlE3KG6PMYLTRW5ITVJ?
D-283MEDNGTIdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLKTWM2OD12OT62NUBvVQ>?MUPTRW5ITVJ?
SW982NGXsPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvGTWM2OD12OT65NUBvVQ>?NH20V21USU6JRWK=
SW620MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTVyLkO2JI5OMnPlV2FPT0WU
KYSE-140MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\XTlVKSzVyPUWwMlU2KG6PM1G1b3NCVkeHUh?=
GCIYMkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPmTWM2OD13MD62O{BvVQ>?M3XiNHNCVkeHUh?=
MHH-ESS-1NXyxcVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTuTWM2OD13MT65OUBvVQ>?M1G2OnNCVkeHUh?=
D-423MGNVf4eI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1y0UmlEPTB;NUKuNFghdk1?M3HIfXNCVkeHUh?=
SF539MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2D6WmlEPTB;NUKuN|Uhdk1?MVvTRW5ITVJ?
RPMI-2650MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLIZpRQUUN3ME21Nk43QSCwTR?=M2jSRXNCVkeHUh?=
GR-STNEn1[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlS2TWM2OD13Mj64O{BvVQ>?M1fvc3NCVkeHUh?=
YKG-1NFj2emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f1e2lEPTB;NUOgcm0>NHnNUIpUSU6JRWK=
SK-MES-1M2GwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX0TWM2OD13Mz6yOkBvVQ>?M{DtbnNCVkeHUh?=
HLENHnsWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVKwTFB5UUN3ME21N{41PyCwTR?=NF\Ge3dUSU6JRWK=
RVH-421MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTV|Lk[3JI5OMYLTRW5ITVJ?
C32NEfMPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;4cVRKSzVyPUWzMlg{KG6PNUO0ZWRtW0GQR1XS
GB-1NIXsbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml21TWM2OD13ND6yJI5OMWXTRW5ITVJ?
SNB75M2jScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTV2LkK2JI5OMnHlV2FPT0WU
EM-2M1jweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfTNlV4UUN3ME21OE41KG6PNFfsSnBUSU6JRWK=
RH-1M3i1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTV2Lkegcm0>M4jMVXNCVkeHUh?=
NKM-1M3rD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTZTWM2OD13ND64NUBvVQ>?M1nNfHNCVkeHUh?=
NCI-H2405M3j6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnUO|V[UUN3ME21OE45QCCwTR?=NXXzXHhyW0GQR1XS
KYSE-450M2fPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjHUJpZUUN3ME21OU4yPiCwTR?=MkLwV2FPT0WU
A704M1Hncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfOdXZKSzVyPUW1MlU6KG6PNX3GO2t7W0GQR1XS
HAL-01MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTV3LkizJI5OM1z1OXNCVkeHUh?=
TE-11NX;0[FVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvZWWhKSzVyPUW1Mlk6KG6PNUHWZZdqW0GQR1XS
DOKNWDzSmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfy[|d4UUN3ME21Ok4xOiCwTR?=MYfTRW5ITVJ?
KY821M{D5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1SxNmlEPTB;NU[uNkBvVQ>?NE\6WWtUSU6JRWK=
KGNNFvaRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTV4LkOyJI5OMV7TRW5ITVJ?
MC116MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTV5Lkigcm0>Mki5V2FPT0WU
PANC-08-13M3n0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rp[WlEPTB;NUiuNFEhdk1?M1zy[HNCVkeHUh?=
KE-37NI\zW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTV6Lke3JI5ONWHjboRuW0GQR1XS
KYSE-410M3;NTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn34TWM2OD13OT60O{BvVQ>?NHzQfY9USU6JRWK=
RO82-W-1NUfuZohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTV7Lkmgcm0>MULTRW5ITVJ?
M14NGjFeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfMTWM2OD14MD6wOEBvVQ>?NFXSbZNUSU6JRWK=
GI-1MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlK0TWM2OD14MD6zJI5OMV7TRW5ITVJ?
ML-2NVrsNHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTjfoI4UUN3ME22NE43OiCwTR?=MXHTRW5ITVJ?
BFTC-905Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoraTWM2OD14MD62OUBvVQ>?M2XMd3NCVkeHUh?=
DMS-273NXzqdZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ztfWlEPTB;NkCuPFchdk1?NUTqcI1OW0GQR1XS
MDA-MB-361MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXFOZJuUUN3ME22NUBvVQ>?MYjTRW5ITVJ?
MSTO-211HNYLERVlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\qTWM2OD14Mz61NUBvVQ>?M{\EfHNCVkeHUh?=
MEG-01M1m2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTZ|LkWyJI5OMn;IV2FPT0WU
M059JMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnpdWNKSzVyPU[zMlU5KG6PM4fKcnNCVkeHUh?=
LN-405MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXnTWM2OD14Mz64OUBvVQ>?NIXsTodUSU6JRWK=
NCI-H1581MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnRRndKSzVyPU[0MlA{KG6PMmPCV2FPT0WU
TCCSUPM1LucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnK5TWM2OD14ND61N{BvVQ>?M1LydHNCVkeHUh?=
SW872NYP4enFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDKTFlKSzVyPU[0MlU4KG6PMUnTRW5ITVJ?
KYSE-510MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDt[YJ3UUN3ME22OU44PSCwTR?=NYTzOnhuW0GQR1XS
NCI-H1792NHXYSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLCbVFiUUN3ME22Ok4yPSCwTR?=NFLvOWFUSU6JRWK=
SW13MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIC5Z49KSzVyPU[2MlUhdk1?M{XuZXNCVkeHUh?=
TE-8MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTZ4LkWyJI5ONU\nPGN6W0GQR1XS
SCHMnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTjTWM2OD14Nz6xJI5ONXjCNpk2W0GQR1XS
NEC8NXvjeW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTZ5LkK0JI5ONHG3dnBUSU6JRWK=
HuO-3N1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTqR|ZEUUN3ME22O{4{OSCwTR?=M37YWnNCVkeHUh?=
EFM-19NYnvbWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPJN5FKSzVyPU[3MlUhdk1?M3\hdXNCVkeHUh?=
HEC-1NF;1[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkO1TWM2OD14Nz61NkBvVQ>?MojWV2FPT0WU
T47DM2nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTZ5Lki3JI5ONUPNRmRjW0GQR1XS
SNU-423NYnWT|NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTZ5Lkm4JI5OMkf3V2FPT0WU
WM-115M363cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDDdmZKSzVyPU[4MlE1KG6PM1;tenNCVkeHUh?=
CaR-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NImzXodKSzVyPU[4MlI2KG6PNGHZT4JUSU6JRWK=
KU812NHz5e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITiemZKSzVyPU[4MlY6KG6PM2jVb3NCVkeHUh?=
AM-38M4PoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTZ7LkOxJI5ONYjTUphKW0GQR1XS
KOSC-2M3f5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\rb4tGUUN3ME22PU46PyCwTR?=NWLuXXlvW0GQR1XS
MC-IXCM1PpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XDXmlEPTB;N{CuNFghdk1?MXTTRW5ITVJ?
SCC-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzLTWM2OD15MT6zPEBvVQ>?NYLCZlBsW0GQR1XS
Calu-3NFPkS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlviTWM2OD15MT65PEBvVQ>?MmrMV2FPT0WU
RPMI-8866M3vSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\xRpNKSzVyPUeyMlgzKG6PNXTGNnNDW0GQR1XS
OVCAR-4NUDUSXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\CTmlEPTB;N{OuN|Yhdk1?MXLTRW5ITVJ?
OAW-42NH\FS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTd|LkO5JI5OM3jJd3NCVkeHUh?=
ATN-1NVPIPIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvy[VdKSzVyPUezMlg4KG6PNH3ibHhUSU6JRWK=
CHP-212MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVf5S4ZFUUN3ME23OE46PSCwTR?=NH3ZdldUSU6JRWK=
C2BBe1NHm1fFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\ZcWlEPTB;N{WuNFMhdk1?M33xWHNCVkeHUh?=
A498MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDjTWM2OD15NT6xOUBvVQ>?MkfRV2FPT0WU
SH-4NESyU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTd3LkKxJI5OM13SNnNCVkeHUh?=
SNU-449M2e5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvwVlJZUUN3ME23OU44QSCwTR?=NGW0PG1USU6JRWK=
RDNHTzc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTd3Lki2JI5OM4TSS3NCVkeHUh?=
PANC-03-27NH3mZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLtT3ZKSzVyPUe2MlI2KG6PMWHTRW5ITVJ?
S-117MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLRV4N4UUN3ME23Ok4zPyCwTR?=Moj2V2FPT0WU
SK-MEL-2Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HWXWlEPTB;N{[uO|Uhdk1?MnPKV2FPT0WU
LK-2Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTd5LkC1JI5OM{Oy[nNCVkeHUh?=
CP50-MEL-BNIHK[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTmVJVJUUN3ME23O{41KG6PMofVV2FPT0WU
647-VMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTd6LkC3JI5OMXLTRW5ITVJ?
LU-134-ANWDGd4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPVe4NIUUN3ME23PU4xOyCwTR?=MnruV2FPT0WU
5637Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LkPGlEPTB;N{muNlMhdk1?MXrTRW5ITVJ?
NCI-H1437MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRThyLkWgcm0>NF6yRVdUSU6JRWK=
NCI-H460NWLidYdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIWwNVhKSzVyPUixMlI{KG6PMl\sV2FPT0WU
BxPC-3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRThzLkS2JI5ONYPNNmZ1W0GQR1XS
CANMorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO1TWM2OD16MT64OEBvVQ>?MWPTRW5ITVJ?
KINGS-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;hcYdKSzVyPUiyMlMzKG6PMkTOV2FPT0WU
OCUB-MMn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTh{LkSxJI5OMkX5V2FPT0WU
KALS-1NH7qN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHThWGNKSzVyPUiyMlU1KG6PNEXGTpJUSU6JRWK=
OCI-AML2MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnQ[3dtUUN3ME24Nk43OSCwTR?=MljqV2FPT0WU
A253NW[1cZY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGryRm9KSzVyPUiyMlY2KG6PNUC5O|VvW0GQR1XS
LCLC-97TM1NVP4UHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XGZmlEPTB;OEKuPFYhdk1?M{\3VHNCVkeHUh?=
NCI-H520NFn3eYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPHTWM2OD16Mz6wOkBvVQ>?Ml\2V2FPT0WU
P30-OHKM4XPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLHSXRNUUN3ME24N{42KG6PMlLaV2FPT0WU
SBC-5NFvCRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTh|LkWyJI5OM4PXOHNCVkeHUh?=
HCE-TNVPQephST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL6PWdKSzVyPUizMlc1KG6PNWX4XGhSW0GQR1XS
JEG-3MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTh2LkGgcm0>NGDERYZUSU6JRWK=
KG-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEja[GFKSzVyPUi0MlI1KG6PMmfUV2FPT0WU
MIA-PaCa-2Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPlTWM2OD16ND61OEBvVQ>?MWnTRW5ITVJ?
CAL-33M3frUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGWyV5FKSzVyPUi1MlA5KG6PM360bHNCVkeHUh?=
639-VMorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTh3LkSyJI5ONF;iPYhUSU6JRWK=
NCI-H1048M{GxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknWTWM2OD16Nj6zNUBvVQ>?NYLDVHFTW0GQR1XS
NCI-H1573NVTv[|l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vNR2lEPTB;OEeuOFghdk1?NHnJXmxUSU6JRWK=
NCI-H2228MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjuS2pKSzVyPUi4MlI3KG6PNET1cZVUSU6JRWK=
NB14MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTh6LkOgcm0>NGW2fWFUSU6JRWK=
SCC-25NFT1UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLXTWM2OD16OT64NkBvVQ>?MX3TRW5ITVJ?
A431MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTFeXNKUUN3ME24PU46PyCwTR?=MlvyV2FPT0WU
SN12CM3;2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3e1N2lEPTB;OUCuOlIhdk1?MVXTRW5ITVJ?
HuCCT1MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTlyLke2JI5OMYnTRW5ITVJ?
LS-123M{LOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXywe3VjUUN3ME25Nk4yQCCwTR?=M1qyfHNCVkeHUh?=
CAL-85-1NH;D[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\ETWM2OD17Mj60PEBvVQ>?MXvTRW5ITVJ?
ES6NUnLVIprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n0XGlEPTB;OUKuPFMhdk1?MVvTRW5ITVJ?
NCI-H650NWXyd4RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLnTWM2OD17ND6wPUBvVQ>?NWKzUHI2W0GQR1XS
NCI-H446NF7IZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrHTWM2OD17NT6xNkBvVQ>?NXfOPVU4W0GQR1XS
EW-13Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PORmlEPTB;OUWuO|Uhdk1?NF;QR4RUSU6JRWK=
HSC-2MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInL[oZKSzVyPUm1Mlg6KG6PMlfaV2FPT0WU
U031NYT2doQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LrNGlEPTB;OU[uO|Mhdk1?NHfSPI1USU6JRWK=
EW-11M4\3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorLTWM2OD17Nj64PEBvVQ>?MYXTRW5ITVJ?
GAKNWTWUGpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfLTWM2OD17OD65N{BvVQ>?NFzEdYhUSU6JRWK=
SK-OV-3NWDsTWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4W3dmlEPTB;MUCwMlA4KG6PNH7xclhUSU6JRWK=
OMC-1M4PwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXqfXFXUUN3ME2xNFAvOThibl2=MmDJV2FPT0WU
TK10MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LobWlEPTB;MUCwMlIyKG6PM{D6bXNCVkeHUh?=
EKVXMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzWcWpJUUN3ME2xNFAvPiCwTR?=NHT6To9USU6JRWK=
Detroit562NFTtSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTFyMj6xO{BvVQ>?MnTvV2FPT0WU
SF268Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTFyMj6zOEBvVQ>?NHjTPZRUSU6JRWK=
SNU-387MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTFyND6xO{BvVQ>?NV3uN|E4W0GQR1XS
MDA-MB-231NWqyflV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTFyNT6wOkBvVQ>?MkX2V2FPT0WU
NCI-H1563NVnMTnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\DTWM2OD1zMEWuNVghdk1?MYnTRW5ITVJ?
D-502MGMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTFyNT63JI5OMkTWV2FPT0WU
A2780MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnvTWM2OD1zME[uOFchdk1?MVHTRW5ITVJ?
IA-LMMlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfhUY54UUN3ME2xNFcvPTFibl2=MUDTRW5ITVJ?
D-392MGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFyNz61OEBvVQ>?MVjTRW5ITVJ?
MS-1MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33HZWlEPTB;MUC3MlcyKG6PM13QW3NCVkeHUh?=
SW1990NVHqcFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnneIxLUUN3ME2xNFgvPTRibl2=MmTPV2FPT0WU
HELNYLuUFBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrRUI1KSzVyPUGwPU4zQSCwTR?=NGizdVNUSU6JRWK=
SW1573NX3O[4tLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjDbndKSzVyPUGwPU4{OSCwTR?=NEXi[FRUSU6JRWK=
SW1783NVXrUZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\mTWM2OD1zMUCuNlIhdk1?MXrTRW5ITVJ?
COLO-680NMnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTFzMD63OkBvVQ>?NYXGWXExW0GQR1XS
NCI-N87MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPzVolpUUN3ME2xNVEvODRibl2=Mn36V2FPT0WU
SK-MEL-28NXrMOnJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrse2d4UUN3ME2xNVEvPTVibl2=M{HVe3NCVkeHUh?=
BT-20NIPZOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T5WmlEPTB;MUGyMlAyKG6PNWTMToplW0GQR1XS
NCI-H1648NWO4bZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O5dGlEPTB;MUGzJI5OMnTZV2FPT0WU
no-11NFrkUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFzMz6yPEBvVQ>?M3TPN3NCVkeHUh?=
MOLT-13M2fmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrkZoJ3UUN3ME2xNVMvPDRibl2=Mn3HV2FPT0WU
NCI-H2170Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTzdlN6UUN3ME2xNVQvPTFibl2=NXPRSYw6W0GQR1XS
HTC-C3M1;SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnUSnFPUUN3ME2xNVYvQDVibl2=MYXTRW5ITVJ?
LU-99AMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXsU3IzUUN3ME2xNVcvOjFibl2=M1PxWHNCVkeHUh?=
HCC2998MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXMdlN4UUN3ME2xNVcvQTJibl2=NVLQ[lEzW0GQR1XS
NB13MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7TWZl2UUN3ME2xNVcvQTlibl2=MV\TRW5ITVJ?
GT3TKBM370V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2L0UGlEPTB;MUG4MlA5KG6PMlGxV2FPT0WU
BT-549MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTFzOD65OUBvVQ>?MlPXV2FPT0WU
NCI-H747MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlz1TWM2OD1zMUmuN|Qhdk1?NFThPXFUSU6JRWK=
EW-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37EeGlEPTB;MUKwMlIhdk1?MkjwV2FPT0WU
LB831-BLCNXO3Vm44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TKVWlEPTB;MUKwMlY{KG6PNIrrfpRUSU6JRWK=
NMC-G1M3;TRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTF{MT6xNUBvVQ>?M4rhdXNCVkeHUh?=
COLO-679Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M332ZWlEPTB;MUKyMlE2KG6PMYnTRW5ITVJ?
HL-60NETGWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHhSphKSzVyPUGyN{4yKG6PMor3V2FPT0WU
MKN7NU\sVmxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVflfplyUUN3ME2xNlMvQDNibl2=NHvvR2hUSU6JRWK=
RERF-LC-MSNFPNVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXGTWM2OD1zMkSuN|Ehdk1?M4noVHNCVkeHUh?=
DMS-114NV6yemxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTPTWM2OD1zMkWuNFkhdk1?M{XLPHNCVkeHUh?=
HuP-T4NUDtNXBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn5dWl5UUN3ME2xNlYvQTdibl2=NYHsfnVOW0GQR1XS
HCC2157M1K4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHEZ21KSzVyPUGyO{42KG6PMXjTRW5ITVJ?
SKG-IIIaNYnVb2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fscGlEPTB;MUK4Mlghdk1?MkG0V2FPT0WU
HCT-116MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDGdFhKSzVyPUGzNE43PCCwTR?=NUPTXpZ4W0GQR1XS
BB30-HNCM1rJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXxZ|drUUN3ME2xN|AvPzhibl2=NYfaUXlQW0GQR1XS
KYSE-270NGfD[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXlTWM2OD1zM{CuPFghdk1?NWDVUpNtW0GQR1XS
MFM-223MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTF|MT61NUBvVQ>?MlrwV2FPT0WU
NH-12NH3JXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTkTWM2OD1zM{KuPVkhdk1?NHe1T4xUSU6JRWK=
U-118-MGNFrVVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HQTmlEPTB;MUOzMlYzKG6PNEHBVmpUSU6JRWK=
ESS-1NGHMRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFH3W5lKSzVyPUGzOU4yQCCwTR?=MmfGV2FPT0WU
D-247MGM3jyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTQ[4FpUUN3ME2xN|UvOjFibl2=M{fqS3NCVkeHUh?=
IGROV-1M4K3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF|NT63OkBvVQ>?MnK1V2FPT0WU
C-33-AMknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTF|NT65O{BvVQ>?NUfIXoduW0GQR1XS
NCI-H1693MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF|Nj6xNkBvVQ>?NW\SZlJUW0GQR1XS
MLMAM3X4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2robmlEPTB;MUO2MlU5KG6PMWXTRW5ITVJ?
SK-N-ASNEfqdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3z1b2lEPTB;MUO3MlE4KG6PNV3rZ|FNW0GQR1XS
NCI-H1755NGn6OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\mVZhUUUN3ME2xN|gvQDVibl2=M1e1cXNCVkeHUh?=
CHP-134MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFX5SnZKSzVyPUGzPU42PSCwTR?=MVXTRW5ITVJ?
LS-513NH;iWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fqVGlEPTB;MUSwMlkyKHCPNIjVNFJUSU6JRWK=
TE-12MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvQV4pKSzVyPUG0NE46OyCwTR?=MkjUV2FPT0WU
KNS-42MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorjTWM2OD1zNESuN{BvVQ>?MoW2V2FPT0WU
SJRH30NX:weJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF2ND60OEBvVQ>?NV7IeW9jW0GQR1XS
NCI-H1092Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTF2ND61NkBvVQ>?MVrTRW5ITVJ?
H-EMC-SSNI\zd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvGfoNpUUN3ME2xOFYvQDFibl2=NWG4RnU6W0GQR1XS
SK-MEL-3MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrMTWM2OD1zNEeuOVUhdk1?MV;TRW5ITVJ?
SK-N-FINEHkSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXX[5MzUUN3ME2xOFcvPTlibl2=MnKzV2FPT0WU
NCI-H2126NEDwTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHZTWM2OD1zNEiuNVUhdk1?MnvrV2FPT0WU
NCI-H1299NWPVVXkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHvN|dHUUN3ME2xOVAvOjJibl2=NW\1dHdLW0GQR1XS
CFPAC-1NWDFZnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTF3MD62OkBvVQ>?MlvhV2FPT0WU
NCI-H661MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTF3MT6yOkBvVQ>?NXfKUHFpW0GQR1XS
KYSE-70M4Hhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3MTZdKSzVyPUG1NU44QSCwTR?=NV[xXHE4W0GQR1XS
SW900MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTEcpU4UUN3ME2xOVQvPjVibl2=M3XMfnNCVkeHUh?=
Ca-SkiNF2yV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml63TWM2OD1zNU[uN|khdk1?NGL5Oo9USU6JRWK=
HPAF-IIM3L2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF3Nj60O{BvVQ>?NYPaXFNwW0GQR1XS
LB2518-MELM4jE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG[z[GVKSzVyPUG1O{4yKG6PNFPZd4pUSU6JRWK=
LC-2-adM17YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C0PGlEPTB;MUW4MlYzKG6PMUPTRW5ITVJ?
HCC1806M2mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTF4Nz64PEBvVQ>?NVO3OGZ1W0GQR1XS
UACC-62M3nHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn71TWM2OD1zNkiuNFkhdk1?M3\aNnNCVkeHUh?=
KM-H2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vJVGlEPTB;MUewMlU5KG6PNILmSVhUSU6JRWK=
NCI-H2347M3HJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonaTWM2OD1zN{KuO|Ihdk1?NVLhNoc1W0GQR1XS
SCC-15Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULKbYNlUUN3ME2xO|MvPjZibl2=M4XQOHNCVkeHUh?=
BB49-HNCNF;6RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u2SWlEPTB;MUezMlgyKG6PM2T0d3NCVkeHUh?=
GMS-10NIDrVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2C5bWlEPTB;MUezMlk1KG6PNX2wUFdJW0GQR1XS
NCI-H2052NVixbYR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7yVG1KSzVyPUG3OE46KG6PMonnV2FPT0WU
SW626M{OyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHCTWM2OD1zN{[uNFYhdk1?MY\TRW5ITVJ?
MDA-MB-415M1Lye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDJOmtbUUN3ME2xO|YvPjFibl2=MnjmV2FPT0WU
Saos-2NHrxT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlewTWM2OD1zN{muN|Uhdk1?NUfp[WxNW0GQR1XS
DK-MGM3r6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXKwVW1iUUN3ME2xPFAvOyCwTR?=M4XNZ3NCVkeHUh?=
SNU-C2BNGG2eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHw[IZtUUN3ME2xPFAvPzNibl2=M1z1V3NCVkeHUh?=
A427NVjXbXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLhWmRKSzVyPUG4Nk42PyCwTR?=MXLTRW5ITVJ?
KP-N-YSNWO3WmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVS1RoNPUUN3ME2xPFUhdk1?MVTTRW5ITVJ?
J82MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrlUXFKSzVyPUG4OU4yQCCwTR?=NEXkUVdUSU6JRWK=
LS-411NMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;4e21lUUN3ME2xPFcvOjhibl2=MVTTRW5ITVJ?
HCC1937NIDXWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF6Nz60PUBvVQ>?M2TZSXNCVkeHUh?=
OE33NHThcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF6OD65O{BvVQ>?NHexe21USU6JRWK=
NB7M2\rXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rMXGlEPTB;MUi5Mlg6KG6PNXPsWHpQW0GQR1XS
SW684MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f0N2lEPTB;MUm2MlE{KG6PM{\1XHNCVkeHUh?=
HT-144NV3DOGttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF7Nj6xOUBvVQ>?MmLNV2FPT0WU
SK-MEL-30NWHUSnBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTF7Nj6yJI5OMXTTRW5ITVJ?
DBTRG-05MGM4XPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHhN4dLUUN3ME2xPVgvPDdibl2=NVqxOHRxW0GQR1XS
NCI-H1395MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjkWVZKSzVyPUG5PE45PSCwTR?=MnyxV2FPT0WU
NCI-H2122NIDOVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTJTWM2OD1{MECuOVkhdk1?M1LCN3NCVkeHUh?=
no-10MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnyTJlKSzVyPUKwNU4xPCCwTR?=MWLTRW5ITVJ?
SW48NV74PHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjSTWM2OD1{MEGuN|Ehdk1?NF\BV41USU6JRWK=
NCI-H1650NXnze4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJyND6wNUBvVQ>?M2HhVnNCVkeHUh?=
MZ1-PCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTJyNT61PEBvVQ>?MmC3V2FPT0WU
U-266Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHLT|VPUUN3ME2yNFUvPzlibl2=NVrVcppJW0GQR1XS
CAS-1NFzyfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1W2eWlEPTB;MkC3MlQ1KG6PM1;1RnNCVkeHUh?=
AU565M3zxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFj2WVZKSzVyPUKxNk45OiCwTR?=MkC5V2FPT0WU
UACC-257NGqxW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYD6[XhDUUN3ME2yNVMvQTlibl2=NY\2[HFPW0GQR1XS
CAL-27M4P2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTJzNz6wOUBvVQ>?NFP0RXFUSU6JRWK=
NCI-H23MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17WTmlEPTB;MkG5MlM{KG6PMnfIV2FPT0WU
TE-6NXjzU3pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHjfIFKSzVyPUKxPU43QCCwTR?=NX7nVlBkW0GQR1XS
TGBC24TKBNFzqRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTJ{Mj6xO{BvVQ>?NHzOelVUSU6JRWK=
TE-1NG\nd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn60TWM2OD1{MkKuPFghdk1?NVzWRYdbW0GQR1XS
RCC10RGBMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfv[45NUUN3ME2yNlQvOTlibl2=M3eyfHNCVkeHUh?=
NCI-H596MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTJ{OD6yNkBvVQ>?NYGyVYZsW0GQR1XS
SW954NF\UfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnWSGZ4UUN3ME2yN|MvQDNibl2=M1LJeXNCVkeHUh?=
NCI-H2087MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTJ|ND61NUBvVQ>?NHHmbmJUSU6JRWK=
SK-PN-DWMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEWxRZNKSzVyPUKzOU4yQSCwTR?=NUHKU29xW0GQR1XS
KM12MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIKzS4ZKSzVyPUKzOU44KG6PMVHTRW5ITVJ?
BT-474M{PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWexd|ZqUUN3ME2yN|UvPzNibl2=MWLTRW5ITVJ?
IST-MES1NG\sSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\YW4ptUUN3ME2yN|YvPTdibl2=NF3GWYFUSU6JRWK=
HT-1197NGXQRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1G4VGlEPTB;MkO4MlA6KG6PNFTiZmpUSU6JRWK=
CAL-54NXnYelNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLuNFVKSzVyPUKzPE41QSCwTR?=NF7iN4hUSU6JRWK=
NB10Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjQVYRtUUN3ME2yOFAvODZibl2=NXHvb2pVW0GQR1XS
PANC-10-05NGrWb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vzcmlEPTB;MkS1MlU3KG6PM3fodXNCVkeHUh?=
NCI-H522NHr6PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{SycWlEPTB;MkS4MlMyKG6PM3yzO3NCVkeHUh?=
A388M2WycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jIPGlEPTB;MkS5MlgzKG6PM2HIO3NCVkeHUh?=
GOTOMm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3niRWlEPTB;MkWwMlI6KG6PMYrTRW5ITVJ?
KLEM3POO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEC5bYdKSzVyPUK1NU45PyCwTR?=M1vOSXNCVkeHUh?=
KYSE-520NFzpO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4m5PGlEPTB;MkWyMlg3KG6PMontV2FPT0WU
HCE-4M3XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTJ4Mj61JI5OMkfhV2FPT0WU
KURAMOCHIM2niOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknLTWM2OD1{NkWuPUBvVQ>?MmfZV2FPT0WU
HCC38NF3GW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHiR45KSzVyPUK2Ok41QCCwTR?=MmqxV2FPT0WU
FADUNYH3O4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DxdWlEPTB;Mk[2MlY{KG6PMlfYV2FPT0WU
CW-2NHvzeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nuUGlEPTB;Mk[5Mlk3KG6PM{HnWnNCVkeHUh?=
L-428MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\wfmlEPTB;Mke1MlE2KG6PMV7TRW5ITVJ?
HCC1569NULwfWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojOTWM2OD1{N{WuPFQhdk1?M{DpSnNCVkeHUh?=
NCI-H810MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rmXGlEPTB;Mke4MlMyKG6PNF;YV4ZUSU6JRWK=
LB771-HNCNXn6dXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ6NT64OEBvVQ>?Mlj0V2FPT0WU
LCLC-103HNInNZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7vTWM2OD1{OEWuPVkhdk1?NF7wVHhUSU6JRWK=
EFO-21M{\VRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrCdZlKSzVyPUK4O{43QCCwTR?=NHrhN3NUSU6JRWK=
CAL-72NEnZNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG2epB4UUN3ME2yPVMvOTlibl2=Mo[5V2FPT0WU
SCC-9M2ruOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULBTFZKUUN3ME2yPVMvOjJibl2=MkCzV2FPT0WU
COLO-829NFjrSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nyfWlEPTB;Mkm2MlUhdk1?MljLV2FPT0WU
U-87-MGMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTNyMD63N{BvVQ>?NVHEUJZbW0GQR1XS
MZ7-melNX:3foJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLJTVhvUUN3ME2zNlMvPzZibl2=NHLRfpRUSU6JRWK=
NCI-H1770NIjNRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nGfWlEPTB;M{K2Mlc1KG6PMmHoV2FPT0WU
ChaGo-K-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1q4fWlEPTB;M{K4MlEhdk1?Ml\ZV2FPT0WU
SiHaNEf0fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXsSZRKSzVyPUOyPU4zPCCwTR?=NILmc|NUSU6JRWK=
NCI-SNU-5NFLGd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYSx[WlFUUN3ME2zN|YvPzdibl2=NI\zboRUSU6JRWK=
DJM-1Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHVTWM2OD1|NECuN|Mhdk1?M4qzbHNCVkeHUh?=
OE19NYO2cnZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1[2R2lEPTB;M{SwMlU{KG6PNInwdWlUSU6JRWK=
NCI-H1651NWXOWHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTN2ND6xPEBvVQ>?NVvtWYVuW0GQR1XS
COLO-792MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTN3ND60NkBvVQ>?Moj2V2FPT0WU
ACHNMnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTN3Nj63NUBvVQ>?NGLFbXNUSU6JRWK=
TH-3NYDwdZQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;oTWM2OD1|N{muPVUhdk1?M1fXT3NCVkeHUh?=
HT-1376M17DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTN6ND64PEBvVQ>?M{DKW3NCVkeHUh?=
RH-18NV3kUoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDRZoVGUUN3ME2zPVQvPzRibl2=NIHySnpUSU6JRWK=
NB6MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTN7Nj62OkBvVQ>?MWHTRW5ITVJ?
COLO-320-HSRNIGzdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Hp[mlEPTB;NECzMlM4KG6PNYXOXYZqW0GQR1XS
UACC-893Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjNS4JKSzVyPUSwOk41PyCwTR?=MVTTRW5ITVJ?
DSH1M4HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\RTWM2OD12ME[uPVEhdk1?M{jqfHNCVkeHUh?=
TE-10MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\neWlEPTB;NEC3MlAyKG6PMl3OV2FPT0WU
HCC70MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPPTWM2OD12MEmuNlEhdk1?M1i1TnNCVkeHUh?=
TGBC11TKBMmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjhb4ZKSzVyPUSxNE4{OyCwTR?=MVfTRW5ITVJ?
NCI-H727M3;DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorpTWM2OD12MUKuNVEhdk1?M{m1eHNCVkeHUh?=
ALL-PONUf6To1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUj0fGZUUUN3ME20NVUvPjlibl2=MXLTRW5ITVJ?
ABC-1MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PxSGlEPTB;NEKwMlQ2KG6PM1zvS3NCVkeHUh?=
NCI-H69MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkThTWM2OD12Mk[uO|Yhdk1?MnzJV2FPT0WU
GP5dMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLTXYJKSzVyPUSzOE41OSCwTR?=M1LZO3NCVkeHUh?=
UMC-11NGHYRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r3Z2lEPTB;NEW4MlM3KG6PMXfTRW5ITVJ?
RMG-INILYN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zjeWlEPTB;NE[3MlU3KG6PMXnTRW5ITVJ?
YAPCM1iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17wO2lEPTB;NEmwMlYhdk1?NFHQPVBUSU6JRWK=
LS-1034MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPXTWM2OD12OUGuNFYhdk1?Mli3V2FPT0WU
RCM-1MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnz2TWM2OD12OU[uOlghdk1?MWjTRW5ITVJ?
HCC1954M2L5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjLXFNWUUN3ME21NVIvPSCwTR?=MYXTRW5ITVJ?
SK-MEL-24MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTVzNj61NUBvVQ>?MYTTRW5ITVJ?
NB12M2XGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLX[oVKSzVyPUWyPE41OiCwTR?=NXXxXoJuW0GQR1XS
SW756NV7EV5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHy5SWdKSzVyPUW1OE46PiCwTR?=MkjiV2FPT0WU
HCC1187MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LieGlEPTB;NUe1Mlg{KG6PNXTEdGtiW0GQR1XS
NCI-H2342M2XJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml62TWM2OD13OUCuN|khdk1?M4nkfHNCVkeHUh?=
NCI-H2291M4K0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37kTmlEPTB;NUm4MlMyKG6PMmXWV2FPT0WU
OVCAR-3M2n6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXXUItUUUN3ME21PVgvQTZibl2=MlexV2FPT0WU
MHH-NB-11M1j4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEm4O45KSzVyPU[yPU4xOSCwTR?=M3rCRXNCVkeHUh?=
SASM4TBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELFdpVKSzVyPU[1Nk43PyCwTR?=NGntS2FUSU6JRWK=
COLO-824MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDsbFJFUUN3ME22PFkvOzdibl2=MWTTRW5ITVJ?
HCC1395Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j2dGlEPTB;Nkm4MlUhdk1?M{TnR3NCVkeHUh?=
COLO-668NFezSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XVeWlEPTB;N{C2MlEhdk1?MWDTRW5ITVJ?
NCI-H226Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTdyNz64JI5OM3nofHNCVkeHUh?=
NB17NH72e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkS2TWM2OD15MkGuO|Uhdk1?M2W1dHNCVkeHUh?=
SW1463NFjvcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLUTWM2OD15M{muNVkhdk1?MoHUV2FPT0WU
TGWMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjEZ5JKSzVyPUe2NE4yPSCwTR?=NH\xc3lUSU6JRWK=
NCI-H526NGPw[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUizVmFUUUN3ME24NlMvPTNibl2=MWHTRW5ITVJ?
COR-L88MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPRTWM2OD16NEiuNVIhdk1?MlPHV2FPT0WU
NCI-H441MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XHfGlEPTB;OEm1MlIzKG6PNGrnc3VUSU6JRWK=
NCI-H630NYnmNmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33qNWlEPTB;OUGyMlk3KG6PNUnQcXFCW0GQR1XS
Mo-TNWnrN|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDq[|hwUUN3ME25OFcvQDhibl2=NETCTI1USU6JRWK=
JARM1LQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHxNotKSzVyPUm1Ok4zPCCwTR?=NGjx[lBUSU6JRWK=
NCI-H1838M1LiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjZTWM2OD1zLkCyN|g5KM7:TR?=NF;tTIJUSU6JRWK=
DoTc2-4510NXS4[WtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;sWmlEPTB;MT6wO|M4PiEQvF2=NVTnbIlJW0GQR1XS
MKN28NYjmd4ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVO2ZZNmUUN3ME2xMlA6ODJ2IN88US=>MWXTRW5ITVJ?
HuP-T3Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHvTWM2OD1zLkGxPVA2KM7:TR?=M2TuPHNCVkeHUh?=
TE-9NIrI[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M331[2lEPTB;MT6xNlk4OyEQvF2=NGjIR3lUSU6JRWK=
NYNUC1TFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYH4bXlRUUN3ME2xMlE3Pzl{IN88US=>Mn;DV2FPT0WU
HT55MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXe3UGI1UUN3ME2xMlMyOzR2IN88US=>MVTTRW5ITVJ?
SW837NVzuO2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDzTWM2OD1zLkOyPVc5KM7:TR?=NIDQcmdUSU6JRWK=
NCI-H2029NIDCToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFwNEG3PVEh|ryPMYfTRW5ITVJ?
IST-SL1NFHTZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe4fI5{UUN3ME2xMlQ1OjRizszNMlzBV2FPT0WU
COLO-741MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HMfmlEPTB;MT60PVc4OSEQvF2=M3j5U3NCVkeHUh?=
LU-65M1zoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnqwTWM2OD1zLk[yNlQ6KM7:TR?=MkjLV2FPT0WU
NCI-H1304NUPNWpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4f3[WlEPTB;MT62OVQ6QCEQvF2=Mk[3V2FPT0WU
KARPAS-299NIXIcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LZb2lEPTB;MT63PVQ4QSEQvF2=MWrTRW5ITVJ?
NCI-H358NXHhUFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3ITpR5UUN3ME2xMlk2PTB|IN88US=>M4\CXnNCVkeHUh?=
OAW-28NEn4NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7WZmZSUUN3ME2yMlA3QTF7IN88US=>MlSwV2FPT0WU
C8166NHTubXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{WweGlEPTB;Mj62N|M6OiEQvF2=MYfTRW5ITVJ?
COLO-678NYPjbYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLo[2NbUUN3ME2yMlg{PzZ6IN88US=>MUjTRW5ITVJ?
SK-N-DZNIHKTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIe0d|lKSzVyPUKuPFY{QDFizszNNVfVPZhCW0GQR1XS
NCI-H82NEXWNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XR[WlEPTB;Mj65NFM3QSEQvF2=M{PiO3NCVkeHUh?=
JVM-2NX3aSoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTNwMEOxPFgh|ryPNGjqXnJUSU6JRWK=
SW1116MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\1WmlEPTB;Mz6wOVQyOSEQvF2=MoS1V2FPT0WU
MDA-MB-453M3frZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\IfFVKSzVyPUOuNVA1OzlizszNMVPTRW5ITVJ?
Calu-6M4fYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTxTWM2OD1|LkG5PVch|ryPNVzB[XQ3W0GQR1XS
SHP-77M1LoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7MTYxnUUN3ME2zMlUzQCEQvF2=NFTWPZVUSU6JRWK=
Capan-2NXf2R4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTRwM{K1PFEh|ryPNUftXnhYW0GQR1XS
SW948MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTRwN{S3O|kh|ryPNYe0OG5kW0GQR1XS
HDLM-2Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvkPGNUUUN3ME21MlA4PzJ3IN88US=>MWTTRW5ITVJ?
LAN-6NVK0PI9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ztOGlEPTB;Nj6yNVQ6PSEQvF2=M1\VU3NCVkeHUh?=
LU-135M4fFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHGd|lMUUN3ME22MlQ{ODd5IN88US=>NEHPd5lUSU6JRWK=
T84NYPwfpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13vNWlEPTB;Nj65PFY1KM7:TR?=NHLkdYZUSU6JRWK=
CAPAN-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17QV2lEPTB;Nz62NlI{OyEQvF2=M3P0UnNCVkeHUh?=
SW1417M1ezR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfRVplpUUN3ME23MlkyPzNzIN88US=>MWXTRW5ITVJ?
BALL-1NYjxO2tST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33pb2lEPTB;OD61NFQxQSEQvF2=NEDwNFJUSU6JRWK=
HT-29M1;CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\6VmlEPTB;OT6wO|U6QSEQvF2=MlXtV2FPT0WU
C3ANF:3NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTlwOEizPVQh|ryPNWXpSVRlW0GQR1XS
NCI-H1993NHnPTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFyLkWwPFEh|ryPMV\TRW5ITVJ?
SK-MEL-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXHXpR[UUN3ME2xNU43Ojh7IN88US=>NXe1dIdzW0GQR1XS
DU-145NH2xdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF2LkWwOVIh|ryPMo\JV2FPT0WU
KP-N-YNMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfJTWM2OD1zND61NVA{KM7:TR?=NUnVUmtTW0GQR1XS
CCRF-CEMM4H6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInh[nVKSzVyPUG0Mlc5ODlizszNNY\kS|ROW0GQR1XS
ZR-75-30MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXwOolKSzVyPUG2MlM{ODNizszNNYfnZoJGW0GQR1XS
A673M3e0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnpTWM2OD1{MD61OVA4KM7:TR?=MUPTRW5ITVJ?
K-562NWnuU3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJ6LkSxPFMh|ryPMn7WV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro Protein Kinase, PI3K, and mTOR Assays PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.

Cell Assay:

[2]

Cell lines HCT116, DLD-1 and SW480 cells
Concentrations 0-1 μM
Incubation Time 48 hours
Method

The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 103 cells/well, DLD-1: 5.5 × 103 cells/well, SW480: 4.5 × 103 cells/well, DLD-1 PIK3CA mutant: 7 × 103 cells/well, and DLD-1 PIK3CA wild-type: 9 × 103 cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours.

Animal Study:

[1]

Animal Models Female Harlan athymic nude mice
Formulation NMP/polyethylene glycol 300 (10/90, v/v)
Dosages 45 mg/kg
Administration p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Maira SM, et al. Mol Cancer Ther, 2008, 7(7), 1851-1863.

[2] Roper J, et al. PLoS One, 2011, 6(9), e25132.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01856101 Terminated Carcinoma Transitional Cell Cliniques universitaires Saint-Luc- Université Catholique  ...more Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Novartis February 2013 Phase 2
NCT01717898 Terminated Castrate-resistant Prostate Cancer Patients. Charles Ryan|Novartis Pharmaceuticals|University of Calif  ...more Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco January 2013 Phase 1|Phase 2
NCT01658436 Completed Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis November 2012 Phase 2
NCT01628913 Terminated Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis October 2012 Phase 2
NCT01690871 Withdrawn Malignant PEComa (Perivascular Epithelioid Cell Tumors) Novartis Pharmaceuticals|Novartis September 2012 Phase 2

view more

Chemical Information

Download BEZ235 (NVP-BEZ235, Dactolisib) SDF
Molecular Weight (MW) 469.55
Formula

C30H23N5O

CAS No. 915019-65-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMF 18 mg/mL warmed (38.33 mM)
DMSO 0.01 mg/mL (0.02 mM)
Water <1 mg/mL (<1 mM)
In vivo NMP+polyethylene glycol 300 (10+90, v+v) 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

Customer Product Validation (8)


Click to enlarge
Rating
Source Cancer Res 2010 70, 4982-4994. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Detection of lipid kinase activities of PI3K p110α mutants
Cell Lines HEK293T cells
Concentrations
Incubation Time
Results "Evaluation of relative kinase activity of these mutants revealed that mutant P449T exhibited gain of function (>2-fold) compared with wild-type PI3K α (Fig. A). With regard to two hotspot mutants (E545K and H1047R), we examined the effect of NVP-BEZ235 and other PI3K inhibitors on their enzymatic activity and found no striking difference in their efficacies compared with wild-type p110α (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 6029-6039. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Synergism studies, Immunoblot assays, Clonogenic assays
Cell Lines Melanoma cell
Concentrations 0.1-100 μM
Incubation Time 1-24 h
Results One of the proposed mechanisms of resistance to PI3KIs is mutation in the Ras-Raf pathway, which are found in more than half of melanomas. By ANOVA, no association was found between the IC50 values of NVP-BEZ235 and the presence or absence of B-Raf mutations (Fig. A). The targets of NVP-BEZ235, pAkt and pP70S6K, were both decreased with exposure to the drug in a time- and dose-dependent fashion, as shown in Figure B for YUVON and YUSIK cell lines. Clonogenicity was studied in YUVON and YUSIK cells with exposure to the dual PI3K/mTOR inhibitor. As shown in Figure C, NVP-BEZ235 effectively inhibits clonogenicity at low nanomolar concentrations.

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Immunofluorescence staining
Cell Lines MCF7 cells, IGF1R cells
Concentrations
Incubation Time
Results We investigated the effect of IGF-1 stimulation on MCF7/IGF-1R 4-OH-TAM resistance in a structurally and physiologically relevant context by use of a modified 3D culture. Both parental MCF7 (Figure a) and MCF7/IGF-1R cells (Figure b) were responsive to E2 or IGF-1 by forming acini on Matrigel, but the response was significantly larger in MCF7/IGF-1R cells with altered a cinar morphogenesis. inhibition of IGF -1R/ERK/Akt signaling by respective kinase inhibitors restored 4-OH-TAM sensitivity of MCF7/IGF-1R cells in 3D culture (Figure c).

Click to enlarge
Rating
Source Breast Cancer Res 2011 13:R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot, A sulforhodamine B ( SRB) colorimetric assay
Cell Lines MCF7 cells, GF-1R cells
Concentrations 0.01-10 μM
Incubation Time
Results IGF-1-stimulated proliferation was drastically restrained by BEZ235 at either 1 or 10 μM (Figure a).While IGF-1R and ERK signaling remained unaffected in response to IGF-1, the phosphorylation level of Akt was diminished with an increase in the dose of BEZ235, largely at 0.1 μM and entirely at 0.5 μM (Figure b). Likewise, the cell proliferation rate decreased correspondingly to Akt phosphorylation levels, significantly dropping at 0.1μM BEZ235 (Figure c)

Click to enlarge
Rating
Source Eur J Cancer 2010 46, 1111-1121. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method LanthaScreen assay
Cell Lines JFCR39 cell lines
Concentrations 0.016 μM
Incubation Time
Results As shown in Fig. A, NVP-BEZ235 and other inhibitors all inhibited mTOR in a dose-dependent manner. The IC50 values were calculated and are shown in Fig. B. NVP-BEZ235 inhibited mTOR potently, with IC50 value of 0.002 μM. In contrast, ZSTK474, GDC-0941 and LY294002 weakly inhibited mTOR, with IC50 values of 0.377, 0.413 and 3.86μM, respectively. To further demonstrate their selectivity for class I PI3K, the IC50 values of these inhibitors for mTOR were divided by their corresponding IC50s for class I PI3Ka, and the resulting ratios were plotted in Fig. C. Clearly, ZSTK474 and GDC-0941 revealed much higher selectivity for inhibiting class I PI3K than the other two inhibitors. In contrast, NVP-BEZ235 more potently inhibited the activity of mTOR than that of class I PI3K

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-50 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western Blotting
Cell Lines xenografts
Concentrations
Incubation Time
Results Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) supplier | purchase BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) cost | BEZ235 (NVP-BEZ235, Dactolisib) manufacturer | order BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us